Journal Mobile Options
Table of Contents
Vol. 23, No. 3, 2002
Issue release date: May–June 2002 (September 2002)

Expression Profiling of Mammary Carcinoma Cell Lines: Correlation of in vitro Invasiveness with Expression of CD24

Schindelmann S. · Windisch J. · Grundmann R. · Kreienberg R. · Zeillinger R. · Deissler H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Invasiveness and the capacity of tumor cells to form distant metastases are important cellular characteristics associated with a poor prognosis in breast cancer patients. In an approach to find genes that are potentially involved in these processes, RNA species showing different abundance in RNA pools from 12 invasive and 13 noninvasive mammary carcinoma-derived cell lines have been identified by hybridization to cDNA microarrays. CD24, keratin 19, keratin 8, GOB-4 and ezrin-radixin-moesin-binding phosphoprotein 50 were found to be preferentially expressed by noninvasive cells whereas vimentin was confirmed as a characteristic of invasive cells. Only differences in expression higher than 3-fold evident in three independent hybridization experiments were considered significant. For all cell lines, expression of mRNA coding for the adhesion molecule CD24, previously suggested to play an important role during tumor progression to more invasive phenotypes, has been quantified by real-time RT-PCR. Flow-cytometric analyses confirmed that CD24 mRNA reflects the amount of cell surface CD24 (Spearman R = 0.88, p = 10–6). CD24 mRNA was found to be absent or weakly expressed in 9/12 (75%) invasive cell lines compared to 3/13 (23%) noninvasive cell lines. The correlation between CD24 expression and invasiveness was calculated to be highly significant with χ2 = 6.74 and p = 0.0094. Future analyses of primary breast carcinomas are warranted to define the role of CD24 in future diagnostic and therapeutic approaches.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Mareel M, Bracke M, van Roy F: Cancer metastasis: Negative regulation by an invasion-suppressor complex. Cancer Det Prev 1995;19:451–464.
  2. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR, Elkahloun AG: In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999;59:5656–5661.
  3. Perou CM, Sø&;acute;rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al: Molecular portrait of human breast tumours. Nature 2000;406:747–752.
  4. Yang GP, Ross DT, Kuang WW, Brown PO, Weigel RJ: Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucleic Acids Res 1999;27:1517–1523.

    External Resources

  5. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu H-L, Munishkin A, Beauheim C, Harvey S, Ethier SP, Johnson PH: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61:5168–5178.

    External Resources

  6. Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N, Leodolter S, Zeillinger R: Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Res Treat 1999;56:91–97.
  7. Church GM, Gilbert W: Genomic sequencing. Proc Natl Acad Sci USA 1984;81:1991–1995.
  8. Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169–193.
  9. Fogel M, Friedrichs J, Zeller Y, Husar M, Smirnov A, Rotiman L, Altevogt P, Sthoeger ZM: CD24 is a marker for human breast carcinoma. Cancer Lett 1999;143:87–94.
  10. Jackson D, Waibel R, Weber E, Bell J, Stahel RA: CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 1992;52:5264–5270.
  11. Ebener U, Wehner S, Cinatl J, Gussetis ES, Kornhuber B: Expression of markers shared between human haematopoietic cells and neuroblastoma cells. Anticancer Res 1990;10:887–890.
  12. Droz D, Zachar D, Charbit L, Gogusev J, Chretein Y, Iris L: Expression of the human nephron differentiation molecules in renal cell carcinoma. Am J Pathol 1990;137:895–905.
  13. Huang LR, Hsu HC: Cloning and expression of CD24 gene in human hepatocellular carcinoma: A potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995;55:4717–4721.
  14. Senner V, Sturm A, Baur I, Schrell UH, Distel L, Paulus W: CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol 1999;58:795–802.
  15. Pirruccello SJ, LeBien TW: The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986;136:3779–3784.
  16. Kay R, Rosten PM, Humphries RK: CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol 1991;147:1412–1416.

    External Resources

  17. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, Altevogt P: CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385–3395.
  18. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friedrichs J, Altevogt P, Ley K: CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998;12:1241–1251.
  19. Bironaite D, Nesland JM, Dalen H, Risberg B, Bryne M: N-Glycans influence the in vitro adhesive and invasive behaviour of three metastatic cell lines. Tumor Biol 2000;21:165–175.
  20. Friedrichs J, Zeller Y, Hafezi-Moghadam A, Gröne H-J, Ley K, Altevogt P: The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000;60:6714–6722.
  21. Kleene R, Yang H, Kutsche M, Schachner M: The neural recognition molecule L1 is a sialic acid-binding lectin for CD24, which induces promotion and inhibition of neurite outgrowth. J Biol Chem 2001;276:21656–21663.
  22. Stefanova I, Horejsi, Ansotegui IJ, Knapp W, Stockinger H: GPI-anchored cell surface molecules complexed to protein tyrosine kinases. Science 1991;254:1016–1019.
  23. Sammar M, Gulbins E, Hilbert K, Lang F, Altevogt P: Mouse CD24 is a signaling molecule for integrin-mediated cell binding: Functional and physical association with src-kinases. Biochem Biophys Res Commun 1997;234:330–334.
  24. Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J: CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001;166:5567–5577.
  25. Mareel MM, De Bruyne GK, Vandesande F, Dragonetti C: Immunohistochemical study of embryonic chick heart invaded by malignant cells in three-dimensional culture. Invasion Metastasis 1981;1:195–204.

    External Resources

  26. Thompson EW, Yu M, Bueno J, Jin L, Maiti SN, Palao-Marco FL, Pulyaeva H, Tamborlane JW, Tirgari R, Wapnir I, et al: Collagen induced MMP-2 activation in human breast cancer. Breast Cancer Res Treat 1994;31:357–370.

    External Resources

  27. Sø&;acute;rlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869–10874.
  28. Thompson DA, Weigel RJ: HAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun 1998;251:111–116.

    External Resources

  29. Bretscher A, Chambers D, Nguyen R, Recek D: ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu Rev Cell Dev Biol 2000;16:113–143.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50